Thomas J. Schall
#132,744
Most Influential Person Now
Thomas J. Schall's AcademicInfluence.com Rankings
Thomas J. Schallphilosophy Degrees
Philosophy
#6536
World Rank
#9585
Historical Rank
Logic
#3689
World Rank
#4885
Historical Rank

Thomas J. Schallbiology Degrees
Biology
#8870
World Rank
#12007
Historical Rank
Virology
#199
World Rank
#205
Historical Rank
Immunology
#519
World Rank
#536
Historical Rank
Biochemistry
#1310
World Rank
#1430
Historical Rank

Download Badge
Philosophy Biology
Thomas J. Schall's Degrees
- PhD Biochemistry Stanford University
- Doctorate Medicine Harvard University
Why Is Thomas J. Schall Influential?
(Suggest an Edit or Addition)Thomas J. Schall's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Identification of a major co-receptor for primary isolates of HIV-1 (1996) (3874)
- A new class of membrane-bound chemokine with a CX3C motif (1997) (2019)
- Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES (1990) (1458)
- Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion (1997) (1409)
- A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development (2006) (1271)
- Molecular cloning and expression of a receptor for human tumor necrosis factor (1990) (955)
- Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor (1993) (820)
- Chemokine receptors: Gateways to inflammation and infection (1996) (721)
- Chemokines, leukocyte trafficking, and inflammation. (1994) (702)
- Biology of the RANTES/SIS cytokine family. (1991) (694)
- Lymphotactin: a cytokine that represents a new class of chemokine. (1994) (690)
- RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes (1992) (641)
- CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature (2007) (557)
- Activation of dual T cell signaling pathways by the chemokine RANTES. (1995) (509)
- Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes (1993) (503)
- A human T cell-specific molecule is a member of a new gene family. (1988) (496)
- CCR6, a CC Chemokine Receptor that Interacts with Macrophage Inflammatory Protein 3α and Is Highly Expressed in Human Dendritic Cells (1997) (391)
- Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. (2017) (364)
- The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. (2010) (359)
- Regulation of the production of the RANTES chemokine by endothelial cells. Synergistic induction by IFN-gamma plus TNF-alpha and inhibition by IL-4 and IL-13. (1995) (354)
- Chemokine/chemokine receptor nomenclature. (2003) (352)
- Cytomegalovirus encodes a potent alpha chemokine. (1999) (350)
- Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. (1993) (316)
- Overcoming hurdles in developing successful drugs targeting chemokine receptors (2011) (306)
- Potent Immunosuppressive Activities of Cytomegalovirus- Encoded Interleukin-10 (2002) (305)
- Elucidation of CXCR7-Mediated Signaling Events and Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migration by CXCR7 Ligands (2009) (285)
- Cytokine expression by neutrophils and macrophages in vivo: endotoxin induces tumor necrosis factor-alpha, macrophage inflammatory protein-2, interleukin-1 beta, and interleukin-6 but not RANTES or transforming growth factor-beta 1 mRNA expression in acute lung inflammation. (1994) (283)
- Identification of a promiscuous inflammatory peptide receptor on the surface of red blood cells. (1993) (279)
- Expression of the chemokine RANTES by a human bronchial epithelial cell line. Modulation by cytokines and glucocorticoids. (1995) (274)
- C5a receptor (CD88) blockade protects against MPO-ANCA GN. (2014) (244)
- Peritoneal fluid concentrations of the cytokine RANTES correlate with the severity of endometriosis. (1993) (242)
- Cutting Edge: Identification of a Novel Chemokine Receptor That Binds Dendritic Cell- and T Cell-Active Chemokines Including ELC, SLC, and TECK (2000) (225)
- Molecular cloning and functional characterization of human lymphotactin. (1995) (221)
- The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. (2015) (205)
- C-C chemokines induce the chemotaxis of NK and IL-2-activated NK cells. Role for G proteins. (1994) (204)
- Neuronal Fractalkine Expression in HIV-1 Encephalitis: Roles for Macrophage Recruitment and Neuroprotection in the Central Nervous System1 (2000) (203)
- HHV8-encoded vMIP-I Selectively Engages Chemokine Receptor CCR8 (1999) (201)
- Local expression of inflammatory cytokines in human atherosclerotic plaques. (1994) (188)
- Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up‐regulated upon dendritic cell maturation (1999) (188)
- Cytomegalovirus-encoded beta chemokine promotes monocyte-associated viremia in the host. (1999) (184)
- RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils. (1992) (182)
- Evidence for NK Cell Subsets Based on Chemokine Receptor Expression1 (2006) (178)
- CC chemokines induce the generation of killer cells from CD56+ cells (1996) (171)
- Chemokine/chemokine receptor nomenclature. (2002) (171)
- Proteolytic Activation of Alternative CCR1 Ligands in Inflammation1 (2005) (169)
- RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. (1996) (166)
- RANTES induces tyrosine kinase activity of stably complexed p125FAK and ZAP-70 in human T cells (1996) (162)
- Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)‐1β production by synovial T cells (1995) (157)
- CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas (2019) (156)
- Functional and biochemical analysis of the cloned Duffy antigen: identity with the red blood cell chemokine receptor. (1994) (152)
- Mutations in the erythrocyte chemokine receptor (Duffy) gene: the molecular basis of the Fya/Fyb antigens and identification of a deletion in the Duffy gene of an apparently healthy individual with the Fy(a – b–) phenotype (1995) (150)
- Functional Analysis of the Human Cytomegalovirus US28 Gene by Insertion Mutagenesis with the Green Fluorescent Protein Gene (1998) (150)
- Proton NMR assignments and solution conformation of RANTES, a chemokine of the C-C type. (1995) (139)
- Glucocorticoid inhibition of RANTES expression in human lung epithelial cells. (1995) (136)
- Characterization of the human basophil response to cytokines, growth factors, and histamine releasing factors of the intercrine/chemokine family. (1993) (135)
- Avacopan for the Treatment of ANCA-Associated Vasculitis. (2021) (133)
- Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease (2010) (132)
- Chemokine Class Differences in Binding to the Duffy Antigen-Erythrocyte Chemokine Receptor (*) (1995) (131)
- The isolation and sequence of a novel gene from a human functional T cell line (1987) (131)
- Functional and biochemical analysis of the cloned Duffy antigen: identity with the red blood cell chemokine receptor (1994) (129)
- A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease (2013) (123)
- CXCR4 and CCR5 expression delineates targets for HIV-1 disruption of T cell differentiation. (1998) (121)
- Neuronal expression of fractalkine in the presence and absence of inflammation (1998) (110)
- Detection of the chemokine RANTES and endothelial adhesion molecules in nasal polyps. (1996) (106)
- The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells (2011) (101)
- Uncoupling of early signal transduction events from effector function in human peripheral blood neutrophils in response to recombinant macrophage inflammatory proteins-1 alpha and -1 beta. (1993) (99)
- Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. (1999) (98)
- Engagement of major histocompatibility complex class II molecules by superantigen induces inflammatory cytokine gene expression in human rheumatoid fibroblast-like synoviocytes (1992) (97)
- Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study (2016) (97)
- The human erythrocyte inflammatory peptide (chemokine) receptor. Biochemical characterization, solubilization, and development of a binding assay for the soluble receptor. (1993) (92)
- Primary sensory neurons migrate in response to the chemokine RANTES (1998) (90)
- Integrin receptors and RGD sequences in human keratinocyte migration: unique anti-migratory function of alpha 3 beta 1 epiligrin receptor. (1992) (90)
- Chemokines as mediators of allergic inflammation. (1996) (86)
- CXCR7 Protein Is Not Expressed on Human or Mouse Leukocytes (2010) (85)
- Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels (2014) (84)
- RANTES stimulation of T lymphocyte adhesion and activation: role for LFA‐1 and ICAM‐3 (1997) (83)
- Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. (2007) (81)
- Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial (2012) (79)
- Comprehensive Mapping of Poxvirus vCCI Chemokine-binding Protein (2002) (78)
- CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice. (2013) (76)
- Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats (2014) (73)
- Structural basis of ligand interaction with atypical chemokine receptor 3 (2017) (73)
- Cancer associated fibroblast FAK regulates malignant cell metabolism (2020) (72)
- CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. (2012) (70)
- Molecular cloning and expression of the murine RANTES cytokine: structural and functional conservation between mouse and man (1992) (68)
- Macrophage inflammatory protein-1beta induces migration and activation of human thymocytes. (1998) (66)
- Synergistic effect of interleukin-1 beta and tumor necrosis factor alpha on interleukin-8 gene expression in synovial fibroblasts. Evidence that interleukin-8 is the major neutrophil-activating chemokine released in response to monokine activation. (1993) (65)
- Fractalkine--a strange attractor in the chemokine landscape. (1997) (64)
- Production of monocyte chemotactic protein–1 in human type B synoviocytes. synergistic effect of tumor necrosis factor α and interferon-γ (1993) (63)
- Activation of CXCR7 Limits Atherosclerosis and Improves Hyperlipidemia by Increasing Cholesterol Uptake in Adipose Tissue (2014) (63)
- RANTES-induced T cell activation correlates with CD3 expression. (1998) (63)
- IL‐1 activation of endothelium supports VLA‐4 (CD49d/CD29)‐mediated monocyte transendothelial migration to C5a, MIP‐1α, RANTES, and PAF but inhibits migration to MCP‐1: a regulatory role for endothelium‐derived MCP‐1 (1995) (60)
- IL-8-induced signal transduction in T lymphocytes involves receptor-mediated activation of phospholipases C and D. (1995) (59)
- Molecular cloning and functional characterization of a novel member of the C-C chemokine family. (1995) (58)
- RANTES activation of phospholipase D in Jurkat T cells: requirement of GTP-binding proteins ARF and RhoA. (1998) (58)
- Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts. (2018) (58)
- Differential coupling of CC chemokine receptors to multiple heterotrimeric G proteins in human interleukin-2-activated natural killer cells. (1996) (58)
- Chemokine Receptor CCR3 Function Is Highly Dependent on Local pH and Ionic Strength* (1997) (52)
- Uncoupling of cytokine mRNA expression and protein secretion during the induction phase of T cell anergy. (1992) (51)
- Characterization of the Rhesus Cytomegalovirus US28 Locus (2003) (50)
- Overexpression of RANTES using a recombinant adenovirus vector induces the tissue-directed recruitment of monocytes to the lung. (1996) (50)
- Biologic activities of the murine beta-chemokine TCA3. (1994) (50)
- Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cells (2016) (49)
- Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. (2013) (49)
- Corticosteroid inhibition of macrophage inflammatory protein-1 alpha in human monocytes and alveolar macrophages. (1995) (48)
- Human keratinocyte migration on type IV collagen. Roles of heparin-binding site and alpha 2 beta 1 integrin. (1994) (45)
- The chemokine receptor CXCR7 is expressed on lymphatic endothelial cells during renal allograft rejection. (2010) (40)
- CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease. (2018) (40)
- Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2020) (39)
- Induction of chemokine gene expression by major histocompatibility complex class II ligands in human fibroblast-like synoviocytes. Differential regulation by interleukin-4 and dexamethasone. (1994) (39)
- IL-17–Secreting γδ T Cells Are Completely Dependent upon CCR6 for Homing to Inflamed Skin (2017) (38)
- Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration‐resistant prostate cancer models (2018) (38)
- Pathogenic role of CXCR7 in rheumatoid arthritis. (2010) (37)
- Human Macrophage Inflammatory Protein cr ( MIP-lc ~ ) and MIPI ~ Chemoklnes Attract Distinct Populations of Lymphocytes (2003) (36)
- Abduction of Chemokine Elements by Herpesviruses (1998) (34)
- Nonspecific CXCR7 antibodies. (2010) (33)
- Human thymocytes express CCR-3 and are activated by eotaxin. (1999) (32)
- CCR 6 , a CC Chemokine Receptor that Interacts with Macrophage Inflammatory Protein 3 a and Is Highly Expressed in Human Dendritic Cells (1997) (32)
- Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells (2020) (32)
- Proinflammatory Proteases Liberate a Discrete High-Affinity Functional FPRL1 (CCR12) Ligand from CCL2312 (2007) (32)
- Chemokines and myeloid cell recruitment. (2000) (31)
- Molecular Cloning and Functional Characterization of Human MIP-1δ, a New C–C Chemokine Related to Mouse CCF-18 and C10 (1998) (29)
- Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice (2014) (28)
- Optimization of 2-aminothiazole derivatives as CCR4 antagonists. (2006) (27)
- Orally-Administered Chemokine Receptor CCR2 Antagonist CCX140-B in Type 2 Diabetes: A Pilot Double-Blind, Randomized Clinical Trial (2012) (27)
- Chemokine expression in rheumatoid arthritis (1994) (25)
- Orally administered CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer. (2017) (22)
- Expression of human CXCR2 in murine neutrophils as a model for assessing cytomegalovirus chemokine vCXCL-1 function in vivo. (2004) (22)
- Production of monocyte chemotactic protein-1 in human type B synoviocytes. Synergistic effect of tumor necrosis factor alpha and interferon-gamma. (1993) (21)
- 392 PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease (2009) (20)
- Efficacy of Chemokine Receptor Inhibition in Treating IL-36α–Induced Psoriasiform Inflammation (2019) (18)
- CCR9 Antagonists in the Treatment of Ulcerative Colitis (2015) (17)
- Regulation of cytokine and chemokine transcription in a human TH2 type T‐cell clone during the induction phase of anergy (1996) (16)
- A Systemically-Administered Small Molecule Antagonist of CCR9 Acts as a Tissue-Selective Inhibitor of Lymphocyte Trafficking (2012) (16)
- OP0227 Oral C5a Receptor Antagonist CCX168 Phase 2 Clinical TRIAL in Anca-Associated Renal Vasculitis (2014) (14)
- 647 Chemokine Receptor Antagonist CCX282-B (Traficet-En™) Maintained Remission of Crohn's Disease in PROTECT-1 Study (2010) (14)
- Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory & clinical activity in the treatment of Crohn's disease (2007) (14)
- Combination therapy of chemokine receptor inhibition plus PDL-1 blockade potentiates anti-tumor effects in a murine model of breast cancer (2015) (13)
- CCR2-Mediated Uptake of Constitutively Produced CCL2: A Mechanism for Regulating Chemokine Levels in the Blood (2019) (13)
- CCR 2 antagonist CCX 140-B provides renal and glycemic benefits in diabetic transgenic human CCR 2 knockin mice (2013) (11)
- Chemokines of the α, β-subclass inhibit human basophils' responsiveness to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 (1995) (10)
- TO012C5A RECEPTOR INHIBITOR AVACOPAN IN IGA NEPHROPATHY STUDY (2017) (10)
- CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis (FSGS) (2018) (10)
- Abstract A107: Inhibition of CCR2 potentiates the checkpoint inhibitor immunotherapy in pancreatic cancer (2016) (10)
- Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complications. (2012) (10)
- Fractalkine Expression in the Rhesus Monkey Brain During Lentivirus Infection and Its Control by 6-Chloro-2',3'-Dideoxyguanosine (2006) (9)
- CCR9 inhibition does not interfere with the development of immune tolerance to oral antigens. (2013) (9)
- Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial (2008) (8)
- Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias (2022) (8)
- CCR 1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease * (2012) (8)
- Cc chemokine receptor 9 (ccr9) antagonist ameliorates experimental ileitis and colitis (2005) (8)
- Therapeutic use of a clinical stage CCR2 inhibitor, CCX872, in obesity-associated steatohepatitis (2014) (8)
- CXCR7 protein expression correlates with elevated mmp-3 secretion in breast cancer cells. (2010) (7)
- Abstract 5655: Inhibition of CCR2 potentiates checkpoint inhibitor immunotherapy in murine model of pancreatic cancer (2017) (7)
- Receptor/ligand interactions in the C-C chemokine family. (1993) (7)
- Tissue proteases convert CCL23 into potent monocyte chemoattractants in patients with chronic rhinosinusitis. (2016) (7)
- A small molecule human PD-1/PD-L1 inhibitor promotes T cell immune activation and reduces tumor growth in a preclinical model (2018) (6)
- Phase 2 randomised trial of oral C5A receptor antagonist CCX168 in ANCA-associated renal vasculitis (2014) (6)
- Expression of the Chemokine Rantes In Human Epithelial-cells (1994) (6)
- PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohnʼs Disease: P-0022. (2009) (6)
- MO039SUCCESSFUL STEROID REPLACEMENT IN ANCA-ASSOCIATED VASCULITIS WITH C5A RECEPTOR INHIBITOR CCX168 IN PHASE 2 RANDOMISED TRIAL (CLEAR) (2016) (5)
- OP0011 A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF AVACOPAN IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS (2020) (5)
- CCR1 Blockade by An Orally-Available CCR1 Antagonist Reduces Tumor Burden and Osteolysis In Vivo In a Mouse Model of Myeloma Bone Disease (2010) (5)
- Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study (2019) (4)
- Chemokine/Chemokine Receptor Nomenclature∗ (2001) (3)
- FRI0002 Inhibition of chemokine receptors ccr1 and ccr6 as promising therapies for rheumatoid arthritis (2013) (3)
- C5aR inhibitor on leukocytes exploratory ANCA associated renal vasculitis (CLEAR) clinical trial with orally administered CCX168 (2013) (3)
- LB791 Avacopan, a highly selective small molecule inhibitor of c5a receptor, in patients with Hidradenitis Suppurativa: Initial results from a randomized, double-blind, placebo-controlled, phase 2 study (aurora) (2021) (3)
- CXCR 7 Ligands Tumor Cell Transendothelial Migration by Events and Inhibition of CXCR 4-Mediated Elucidation of CXCR 7-Mediated Signaling (2009) (3)
- CCR 9 Antagonists in the Treatment of Ulcerative Colitis (2015) (3)
- LB003A RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDY OF AVACOPAN IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS (2020) (2)
- EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY (2013) (2)
- OP0046 Effect of a selective c5ar antagonist, avacopan (CCX168), on plasma complement levels in anca associated vasculitis (AAV) (2018) (2)
- The inhibition of CCR2 to modify the microenvironment in pancreatic cancer mouse model and to support the profiling of the CCR2 inhibitor CCX872-B in patients. (2016) (2)
- POS-112 EFFECT OF AVACOPAN, A SELECTIVE C5A RECEPTOR INHIBITOR, ON COMPLEMENT 3 GLOMERULOPATHY HISTOLOGIC INDEX OF DISEASE CHRONICITY (2022) (2)
- Traficet-EN, an Oral CCR9-Specific Antagonist, Induces High Levels of Remission in the Open-Label Phase of PROTECT-1 in Crohnʼs Disease: 1047 (2008) (2)
- Reduction of Liver Fibrosis by CCR2 Antagonist CCX872 in Murine Models of NASH: 920 (2016) (2)
- CXCR7 Is Expressed in B Acute Lymphoblastic Leukemia (ALL) Cells and Mediates Their Transendothelial Migration. (2008) (2)
- Differences in CXCR7 protein expression on rat versus mouse and human splenic marginal zone B cells. (2013) (2)
- A human T cell-specific molecule is a member of a new gene family. 1988. (2009) (2)
- Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease (2007) (2)
- Phase 2 clinical trial of CCX168, an orally administered C5aR antagonist, in patients with ANCA-associated renal vasculitis (CLEAR) (2013) (2)
- Pillars Article: A Human T Cell-Specific Molecule Is a Member of a New Gene Family. J. Immunol . 1988. 141: 1018–1025 (2009) (2)
- SP457CCR2 INHIBITOR CCX140 EFFECTIVE IN PHASE 2 CLINICAL TRIAL IN DIABETIC NEPHROPATHY (2015) (2)
- Tissue directed recruitment of mononuclear cells to the lung using a recombinant adenovirus expressing murine RANTES (1994) (2)
- Interleukin-16 or not? (1996) (2)
- 521 Chemokine receptor inhibition as a novel therapeutic approach for psoriasis (2016) (2)
- CCR9 Inhibition in the treatment of Colonic Inflammation: O-0011. (2009) (2)
- Diabetes - basic research (2011) (1)
- Recruitment and Neuroprotection in the Encephalitis: Roles for Macrophage Neuronal Fractalkine Expression in HIV-1 (2000) (1)
- Potent Immunosuppressive Activities of Cytomegalovirus-Encoded Interleukin-10 (2002) (1)
- Abstract 5693: Anti-tumor effect of orally available small molecule PD-L1 inhibitors in a murine model of colon adenocarcinoma (2020) (1)
- FP167ADVERSE EVENTS WITH GLUCOCORTICOID STANDARD OF CARE VERSUS AVACOPAN IN ANCA-ASSOCIATED VASCULITIS: OBSERVATIONS FROM THE CLEAR TRIAL (2018) (1)
- T1143 A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Testing CCX282-B in the Treatment of Celiac Disease (2008) (1)
- Erratum: Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10 (Journal of Virology (2002) 76:3 (1285-1292)) (2002) (1)
- 669 Chemokine receptor CCR6 antagonist reverses psoriaform dermatitis by preventing accumulation of γδT17 cells in skin (2017) (1)
- The CCR4 antagonist CCX6239 for the treatment of allergic airways disease (2013) (1)
- Expression of CXCR7, CXCR4, CXCR3 and their chemokine ligands in glioblastoma. (2012) (1)
- Bicyclic compounds as inhibitors of the binding of chemokine to US28. (2002) (1)
- Abstract B26: Tumor reduction by a small molecule human PD-1/PD-L1 inhibitor in a melanoma/PBMC co-implantation model (2020) (1)
- ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap (2016) (1)
- Clinical studies in CKD 1-5 (2012) (1)
- MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B (2008) (1)
- Traficet-EN, an Oral CCR9-Specific Antagonist, induces high levels of remission in the open-label Phase of PROTECT-1 in Crohn's Disease (2008) (1)
- LAB-EXPERIMENTAL (PRE-CLINICAL) THERAPEUTICS AND PHARMACOLOGY (2012) (1)
- Relationship of Histamine-Releasing Factors to the Human Intercrine/Chemokine Group of Cytokine-Like Molecules. (1992) (1)
- IL36-Mediated Skin Inflammation Requires Signaling Through Chemokine Receptor CCR6. (2018) (1)
- Abstract B24: Pharmacokinetic and pharmacodynamic profile of the novel, oral and selective CCR2 inhibitor CCX872-B in a Phase 1B pancreatic cancer trial (2015) (1)
- PROTECT-1: A Prospective Randomized Trial of CCX282-B (Traficet-EN), a Novel Oral Therapy Targeting Chemokine Receptor 9 in Crohnʼs Disease: 972 (2007) (1)
- IMMU-09. DISRUPTION OF THE CCL2-CCR2 AXIS AUGMENTS THE EFFECTS OF IMMUNE CHECKPOINT INHIBITORS TO SLOW PROGRESSION OF GLIOMAS (2017) (1)
- Post-Translational Modification By Serine Proteases Controls The CCL23 Activity In Nasal Polyps Of Chronic Rhinosinusitis (2014) (1)
- CHAPTER 48 – Fractalkine (2003) (1)
- Preliminary data from an ongoing phase 1 dose-escalation study of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors. (2022) (1)
- Inhibitors of the binding of chemokine I-TAC or SDF-1 to the receptor ccxckr2 (2003) (1)
- OP0203 Orally-administered CCR1 antagonist CCX354-C in a phase 2 rheumatoid arthritis study (2013) (0)
- Anti-tumor effects of a small molecule C-C chemokine receptor 4 inhibitor in mouse tumor models (2018) (0)
- P0973ALLOSTERIC C-C CHEMOKINE RECEPTOR TYPE 2 (CCR2) INHIBITION IMPROVES RENAL FUNCTION IN A MURINE MODEL OF DIABETIC NEPHROPATHY (2020) (0)
- Pharmacological inhibition of CCR9 is a novel approach in the treatment of inflammatory bowel disease (2007) (0)
- SP042CREATION OF MOUSE MODELS OF COMPLEMENT MEDIATED RENAL DISEASE USING CRISPR-CAS9 TO INTRODUCE KNOWN HUMAN FACTOR H MUTATIONS IN HUMAN C5A-RECEPTOR KNOCK-IN MICE (2016) (0)
- Contents, Vol. 99, 1992 (1992) (0)
- SHIELD 4 Phase 3 Clinical Trial With Orally Administered CCR9 Inhibitor Vercirnon in Crohn’s Disease: 1681 (2014) (0)
- University of CC Chemokine Receptor 2 Promotes Recruitment of Myeloid Cells Associated with Insulin Resistance in Non-Alcoholic Fatty Liver Disease (2018) (0)
- T Cells: Requirement of GTP-Binding Proteins RANTES Activation of Phospholipase D in Jurkat (2017) (0)
- SaO058CCR2 INHIBITION IMPROVES RENAL FUNCTION & NORMALIZES GLOMERULAR STRUCTURE IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) MODELS (2018) (0)
- P251 THERAPEUTIC USE OF A CLINICAL STAGE CCR2 INHIBITOR, CCX872, IMPROVES OBESITY ASSOCIATED STEATOHEPATITIS IN MICE (2014) (0)
- Compositions and methods for the detection and treatment of diseases associated with chemokine receptors (2002) (0)
- Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan. (2023) (0)
- SP004INHIBITION OF THE C5A RECEPTOR BY CCX168 MARKEDLY REDUCES THE THROMBOGENIC POTENTIAL OF SERUM FROM PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (2015) (0)
- FP240CCR2 INHIBITION IMPROVES RENAL FUNCTION IN MURINE MODELS OF CHRONIC KIDNEY DISEASE (2019) (0)
- Abstract 564: Combination therapy of chemokine receptor inhibition plus PD-L1 blockade potentiates antitumor effects in a murine model of breast cancer (2016) (0)
- Cc ckr-1, a chemokine receptor cc (1993) (0)
- Small Molecule Inhibition of Chemokine Receptor ‘CCR9’ Combined With Anti-α4β7 Blocking Antibody Confers Synergistic Protection Against Piroxicam-Accelerated Colitis in Mice: 1771 (2014) (0)
- The effect of the CXCR7 inhibitor CCX662 on survival in the ENU rat model of glioblastoma. (2012) (0)
- OP0204 Characterization of the novel C5AR antagonist CCX168, a potential therapeutic for ANCA-vasculitis, rheumatoid arthritis, and other autoimmune disorders (2013) (0)
- Pharmacological inhibition of gut homing CCR9 T-cells alters disease severity in murine models of inflammatory bowel disease: O-0007 (2007) (0)
- CCR6, a CC Chemokine Receptor that Interacts with Macrophage Inflammatory Protein 3 (cid:97) and Is Highly Expressed in Human Dendritic Cells (1997) (0)
- Chemokines of the alpha, beta-subclass inhibit human basophils' responsiveness to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. (1995) (0)
- Orally Administered CCR9 Inhibitor CCX507 Effectively Blocks CCR9 in Circulating Human Leukocytes: 1678 (2014) (0)
- FC 032THE EFFECT OF AVACOPAN, A COMPLEMENT C5A RECEPTOR INHIBITOR, ON KIDNEY FUNCTION IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS WITH RENAL DISEASE (2021) (0)
- In Vivo Studies of Rantes and the Recruitment of Lymphocytes to Inflammatory Sites (1993) (0)
- Abstract 17007: CCR2 Antagonist Inhibits Neointimal Proliferation Post CoronaryStent Deployment (2010) (0)
- Differentiation Targets for HIV-1 Disruption of T Cell CXCR4 and CCR5 Expression Delineates (1998) (0)
- CX 3 C chemokine genes of mammals (1997) (0)
- enhancingtheirantitumorcapacities.Theseresultspointouttheinterestofcordbloodasasourceofcellsforadoptivecancerimmunotherapyusingreceptor-engineeredTcells. the in Reducing and increasing long (2017) (0)
- Abstract 1745: Inhibition of chemokine receptor 2 (CCR2) with a small molecule antagonist enhances the effectiveness of checkpoint inhibition by altering the tumor microenvironment in mouse colorectal tumors: Reducing tumor size and increasing long term survival (2018) (0)
- Seven structures of atypical chemokine receptor 3 reveal the molecular bases for its promiscuity and signaling bias (2022) (0)
- TECK Cell-and T Cell-Active Chemokines Chemokine Receptor That Binds Dendritic Cutting Edge : Identification of a Novel (2000) (0)
- Tu1955 Pharmacological Inhibition of C-C Chemokine Receptor 9 (CCR9) Does Not Inhibit the Generation of Oral Tolerance (2012) (0)
- TO041CCR2 ANTAGONISM REDUCES PROTEINURIA AND GLOMERULAR INJURY IN MURINE MODELS OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) (2017) (0)
- Antagonists of chemokine receptor CCR9 synergize with anti-TNFα immunotherapy to reduce inflammation in the MDR1a−/− mouse model of colitis (2020) (0)
- IMMU-05. DISRUPTION OF THE CCR2 CHEMOKINE RECEPTOR PATHWAY OVERCOMES THERAPEUTIC RESISTANCE TO PD-1 BLOCKADE IN MALIGNANT GLIOMA (2019) (0)
- FP017Critical Equilibrium between CCL2 Secretion and Its Constitutive Re-Uptake by CCR2: An Elegant Mechanism for Regulating CCL2 Levels in the Blood (2019) (0)
- Compositions and methods for the detection and treatment of diseases and conditions related to chemokine receptors (2002) (0)
- RANTES and Macrophage Inflammatory Protein lot Induce the Migration and Activation of Normal Human Eosinophil Granulocytes By Antal Rot,* (2003) (0)
- 691 Neutrophil and C5aR dynamics in hidradenitis suppurativa disease progression (2021) (0)
- Abstract 1274: CCX559 is a potent orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity (2021) (0)
- or Mouse Leukocytes CXCR7 Protein Is Not Expressed on Human (2010) (0)
- P032 Genetic deletion and pharmacological inhibition of chemokine receptor 9 (CCR9) result in opposite effects on the development of oral tolerance (2012) (0)
- CX 3 C chemokine genes mammalian cells. (1997) (0)
- Tissue proteases convert CCL23 into potent monocyte chemoattractants in chronic rhinosinusitis (2016) (0)
- IMST-15. PHARMACOLOGICAL ANTAGONISM OF CCR2 IMPACTS PROGRESSION OF MURINE GLIOMAS (2016) (0)
- Fractalkine, a novel CX3C chemokine, is expressed by epidermal melanocytes and langerhans cells (1998) (0)
- CC CKR-1 chemokine receptor (1993) (0)
- 326. A RANDOMIZED PHASE 3 TRIAL EVALUATING THE SAFETY AND EFFICACY OF AVACOPAN IN PATIENTS WITH NEW OR RELAPSING ANCA-ASSOCIATED VASCULITIS (2019) (0)
- 499 The small molecule PD-L1 inhibitor CCX559 preferentially accumulates in tumors, resulting in depletion of cell-surface PD-L1 in a murine preclinical model (2022) (0)
- Latency and myeloid cells (1999) (0)
- Inhibition of CCR9 as a therapeutic approach: beyond the small intestine: P‐072. (2008) (0)
- P0336INHIBITION C-C CHEMOKINE RECEPTOR TYPE 2 (CCR2) ON ACTIVATED KIDNEY PARIETAL EPITHELIAL CELLS REVEALS A NEW THERAPEUTIC APPROACH FOR CHRONIC KIDNEY DISEASES (2020) (0)
- Efficacy of Oral C5aR Inhibitor CCX168 on Non-Renal Disease Activity in Patients withAntineutrophil Cytoplasmic Antibody-Associated Vasculitis (2014) (0)
- POS-375 AVACOPAN IN ANCA-ASSOCIATED VASCULITIS: EVIDENCE FOR ELIMINATION OF DAILY PREDNISONE THERAPY AND REDUCTION IN GLUCOCORTICOID-RELATED TOXICITY FROM THE PHASE 3 ADVOCATE TRIAL (2021) (0)
- Cancer associated fibroblast FAK regulates malignant cell metabolism (2020) (0)
- Cloning and characterization of a novel chemokine-like cytokine (1994) (0)
- Tu1499 Efficacy of a Small Molecule CCR2 Antagonist in Experimental Model of Chronic Pancreatitis (2016) (0)
- Methods and compositions suitable for inducing an immune response (2002) (0)
- W51 THE CXCR7 LIGAND CCX771 REDUCES NEOINTIMA FORMATION AFTER VASCULAR INJURY AND ATHEROSCLEROSIS IN ApoE−/− MICE (2010) (0)
- Antibodies that bind to CCX-CKR2 (2006) (0)
- Abstract CT223: CCX872: Pharmacodynamic study of a potent and selective CCR2 antagonist in human volunteers and plans for phase Ib trial in patients with pancreatic cancer (2015) (0)
- 70PChemokine receptor 2 (CCR2) antagonism with a small molecule enhances the effectiveness of checkpoint inhibition by altering the tumor microenvironment in mouse colorectal tumours: Reducing tumor size and increasing long term survival (2017) (0)
- IMMU-51. THE COMBINATION OF CCR2 ANTAGONIST AND PD-1 BLOCKADE PROLONGS SURVIVAL IN IMMUNE CHECKPOINT INHIBITOR RESISTANT GLIOMAS (2018) (0)
- MO253A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RANGING STUDY (LUMINA-1 STUDY) TO EVALUATE THE SAFETY AND EFFICACY OF CCX140 IN SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROISS (FSGS)* (2021) (0)
- Post-Translational Modification of CCL23 in Chronic Rhinosinusitis with Nasal Polyps (2013) (0)
- CCR2 Inhibition Reduces Tumor‐Associated Myeloid‐Derived Suppressor Cells and Unmasks an α‐PD‐1 Effect to Slow Tumor Progression in Checkpoint Inhibitor Resistant Gliomas (2019) (0)
- Tu1652 CCX507, an Orally Bioavailable Antagonist of the Chemokine Receptor CCR9, for the Treatment of IBD (2013) (0)
- P037 Antagonism of chemokine receptor CCR9 synergises with anti-TNFα immunotherapy to reduce inflammation in the MDR1a−/− mouse model of colitis (2020) (0)
- CR 9 inhibition does not interfere with the development of immune tolerance to ral antigens (2013) (0)
- Abstract B08: C-C chemokine receptor 4 (CCR4) antagonism enhances the effectiveness of checkpoint Inhibition in mouse tumor models (2020) (0)
- 725 Targeting chemokine receptors CCR6 and CXCR2 in a murine model of IL-36α-induced pustular psoriasis. (2019) (0)
- Focus Session 15: Chemokine Antagonists (2014) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Thomas J. Schall?
Thomas J. Schall is affiliated with the following schools: